Mark your calendars for 7 July 2022with Dr. Sue Ellen Carpenter of Atlanta-based Bloom fertility
SARASOTA, Fla., 7 July 2022 / PRNewswire / – INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture (“IVC”) procedure that makes it possible, announced today that dr. Sue Ellen Carpenter of Bloom Fertility, an INVO center in Atlantawill host “Get to Know INVOcell” – a live Facebook event 7 July 2022 by 19:00 ET.
INVOcell induces fertilization and early embryo development within a woman’s body. It offers a personal, intimate experience in creating a baby, shows impressive success rates and makes advanced infertility treatment affordable.
Event link: https://www.facebook.com/hellobloomfertilityclinic/
Dr. Carpenter said, “After both my children experienced infertility, I decided that we needed to address fertility treatment in a new way. That’s why we founded Bloom Fertility and set up an INVO center in Atlanta. I’m here to help. With over 30 years of experience in reproductive medicine, my specialties include fertility evaluation, fertility coaching, ovulation induction, intrauterine insemination, intravaginal culture and IVF. As someone who has dedicated their lives to helping people achieve their parenting goal, I appreciate educating my patients about their diagnosis and treatment options. I look forward to navigating your journey as we develop a unique plan that will help you reach your goal of becoming a parent. “
Interested participants can join the live event 7 July 2022 and can reach out directly to the Bloom Fertility office to schedule a complimentary 15-minute consultation.
Flowering Fertility
6 Concourse Parkway, Suite 250
Atlanta, GA 30328
678-597-9933
www.hellobloomfertility.com
This event follows on from the recent Facebook Live event hosted by Dr. Karen Hammond of Innovative Fertility Specialists (IFS), an INVO center located in Birmingham, AL. A repeat of that live event can be viewed here: https://www.facebook.com/events/759676351734148/?ref=newsfeed
Innovative Fertility Specialists contact information:
Innovative fertility specialists
1 Inverness Center Parkway
Birmingham, AL 35242
205.509.0700
www.ifsinvo.health
About INVO Bioscience
We are a commercial fertility company dedicated to expanding the assisted reproduction technology (“ART”) market by making fertility care accessible and inclusive to people around the world. Our primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. Our flagship product is INVOcell®, a revolutionary medical device that induces fertilization and early embryo development in vivo in the woman’s body. This treatment solution is the world’s first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, referred to as “IVC”, offers patients a more natural, intimate and more affordable experience compared to other ART treatments. We believe the IVC procedure can provide comparable results at a fraction of the cost of traditional in vitro fertilization (“IVF”) and is a significantly more effective treatment than intrauterine insemination (“IUI”). Our commercialization strategy is focused on the opening of dedicated “INVO centers” offered by INVOcell® and IVC procedure (with three centers in North America now in operation), in addition to continuing to distribute and sell our technology solution in existing fertility clinics. For more information, please visit www.invobio.com.
Safe Harbor Statement
This exemption contains forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company calls for the protection of the Private Securities Reform Litigation Act of 1995. All statements regarding our expected future financial position, results of operations, cash flow, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “expect,” “if,” “believe,” “plan,” “estimate,” “expect,” “intended,” “power,” “can,” “belong “,” will “and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which could cause actual results, performance or performance to differ materially from expected results, performance or performance. Factors that may cause actual results to differ materially from those in the prospective statements include those set out in our submissions to www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or change our forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE INVO Bioscience, Inc.
English
French
Spanish